Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan-eluting beads - Biocompatibles

Drug Profile

Irinotecan-eluting beads - Biocompatibles

Alternative Names: CM-BC2; DEBIRI; Irinotecan bead; Irinotecan-loaded DC Bead LUMI™; Irinotecan-loaded DC BeadM1™; Irinotecan-loaded DC Bead™; PARAGON Bead

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocompatibles International
  • Developer Biocompatibles International; BTG; Singapore General Hospital
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Liver metastases
  • Phase II Cholangiocarcinoma
  • Phase I/II Glioma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in Singapore (Intra-arterial)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(Recurrent, Adjuvant therapy) in United Kingdom (Intratumoural, Injection)
  • 29 Jul 2016 BTG International terminates a phase I clinical trials in Glioma (Recurrent, Adjuvant therapy) in United Kingdom (unspecified route) (NCT02433392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top